METHOD OF COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE LIVER METASTASES Russian patent published in 2024 - IPC A61B17/00 A61K31/4375 A61K31/282 A61K31/7068 A61P35/00 A61P35/04 

FIELD: medicine; oncology.

SUBSTANCE: invention can be used for combined treatment of metastatic colorectal cancer (mCRC) in patients with resectable liver metastases. The method includes conducting courses of antitumour drug therapy using irinotecan at a dose of 165 mg/m² using intravenous drip on day 1, oxaliplatin at a dose of 85 mg/m² using intravenously drip on day 1, capecitabine orally daily in two doses, 3 courses of preoperative treatment are used according to the above scheme, radical surgery and 3 courses of adjuvant treatment, while taking capecitabine at a dose of 2,500 mg/m² is carried out from days 1 to 14, the break between the courses is 7 days.

EFFECT: use of the invention improves the results of combined treatment of metastatic colorectal cancer in patients with resectable liver metastases in the presence of mutations in the KRAS genes by increasing the frequency of objective tumour responses and reducing the number of adverse events during antitumour drug treatment, increasing the frequency of performing parenchyma-sparing radical liver resections (R0), and also increasing the overall and relapse-free survival of patients.

1 cl, 2 ex